WO2021162532A3 - Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 - Google Patents
Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2021162532A3 WO2021162532A3 PCT/KR2021/001928 KR2021001928W WO2021162532A3 WO 2021162532 A3 WO2021162532 A3 WO 2021162532A3 KR 2021001928 W KR2021001928 W KR 2021001928W WO 2021162532 A3 WO2021162532 A3 WO 2021162532A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- sustained
- release microspheres
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021219556A AU2021219556A1 (en) | 2020-02-14 | 2021-02-15 | Pharmaceutical composition comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof |
JP2022548939A JP2023513751A (ja) | 2020-02-14 | 2021-02-15 | Glp-1アナログ、またはその薬学的に許容可能な塩を含む徐方型微粒球を含む薬学的組成物 |
EP21754621.7A EP4104820A4 (en) | 2020-02-14 | 2021-02-15 | PHARMACEUTICAL COMPOSITION COMPRISING SUSTAINED-RELEASE MICROSPHERES COMPRISING A GLP -1 ANALOG OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
BR112022016100A BR112022016100A2 (pt) | 2020-02-14 | 2021-02-15 | Composição farmacêutica compreendendo microgrânulos de liberação sustentada incluindo análogo de glp-1 ou sal farmaceuticamente aceitável do mesmo |
US17/904,133 US20230096928A1 (en) | 2020-02-14 | 2021-02-15 | Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof |
MX2022010044A MX2022010044A (es) | 2020-02-14 | 2021-02-15 | Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo. |
CA3167978A CA3167978A1 (en) | 2020-02-14 | 2021-02-15 | Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof |
CN202180027937.6A CN115484935A (zh) | 2020-02-14 | 2021-02-15 | 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200018640 | 2020-02-14 | ||
KR10-2020-0018640 | 2020-02-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021162532A2 WO2021162532A2 (ko) | 2021-08-19 |
WO2021162532A3 true WO2021162532A3 (ko) | 2021-09-30 |
Family
ID=77292774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/001928 WO2021162532A2 (ko) | 2020-02-14 | 2021-02-15 | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230096928A1 (ko) |
EP (1) | EP4104820A4 (ko) |
JP (1) | JP2023513751A (ko) |
KR (2) | KR102375262B1 (ko) |
CN (1) | CN115484935A (ko) |
AU (1) | AU2021219556A1 (ko) |
BR (1) | BR112022016100A2 (ko) |
CA (1) | CA3167978A1 (ko) |
MX (1) | MX2022010044A (ko) |
WO (1) | WO2021162532A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102583029B1 (ko) * | 2020-05-28 | 2023-09-26 | 주식회사 아울바이오 | 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법 |
US11865213B2 (en) | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
AU2022382676A1 (en) * | 2021-11-05 | 2024-05-23 | G2Gbio, Inc. | Pharmaceutical kit for parenteral co-administration |
WO2024010379A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 지투지바이오 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법 |
WO2024077409A1 (en) * | 2022-10-09 | 2024-04-18 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
WO2024128882A1 (ko) * | 2022-12-16 | 2024-06-20 | 주식회사 펩트론 | Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140004198A1 (en) * | 2011-01-19 | 2014-01-02 | Novo Nordisk A/S | Glp-1 particles and compositions |
JP2016515612A (ja) * | 2013-04-03 | 2016-05-30 | ドン クック ファーマシューティカル カンパニー リミテッド | ドネペジルを含む非経口投与用の医薬組成物 |
WO2017186075A1 (zh) * | 2016-04-26 | 2017-11-02 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
KR102047983B1 (ko) * | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
BR112012028136A2 (pt) * | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
CN102940609B (zh) * | 2012-12-12 | 2018-04-06 | 上海苏豪逸明制药有限公司 | 一种高包封率奥曲肽缓释微球及其制备方法 |
CN105126082B (zh) * | 2015-09-22 | 2022-03-04 | 齐鲁制药有限公司 | 一种多肽药物制剂及其制备方法 |
CN106924750B (zh) * | 2015-12-31 | 2021-03-23 | 深圳翰宇药业股份有限公司 | 一种索马鲁肽口服微粒制剂及其制备方法 |
KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
CN107929718A (zh) * | 2017-10-19 | 2018-04-20 | 南京星银药业集团有限公司 | Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法 |
CN110101846B (zh) * | 2018-02-01 | 2022-09-23 | 齐鲁制药有限公司 | 一种低突释率的索玛鲁肽微球及其制备方法 |
CN110623944B (zh) * | 2018-06-20 | 2022-02-08 | 鲁南制药集团股份有限公司 | 一种胰高血糖素样肽-1类似物缓释微球制剂及其制备方法 |
KR102137786B1 (ko) * | 2018-07-19 | 2020-07-24 | 주식회사 아울바이오 | 주사제용 미립구의 제조방법 |
US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
KR102186704B1 (ko) * | 2019-02-18 | 2020-12-04 | (주)아이엠디팜 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
EP4005587A4 (en) * | 2019-07-29 | 2023-08-09 | Peptron, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION |
-
2021
- 2021-02-15 EP EP21754621.7A patent/EP4104820A4/en active Pending
- 2021-02-15 US US17/904,133 patent/US20230096928A1/en active Pending
- 2021-02-15 CA CA3167978A patent/CA3167978A1/en active Pending
- 2021-02-15 KR KR1020210020164A patent/KR102375262B1/ko active IP Right Review Request
- 2021-02-15 JP JP2022548939A patent/JP2023513751A/ja active Pending
- 2021-02-15 AU AU2021219556A patent/AU2021219556A1/en active Pending
- 2021-02-15 MX MX2022010044A patent/MX2022010044A/es unknown
- 2021-02-15 BR BR112022016100A patent/BR112022016100A2/pt unknown
- 2021-02-15 WO PCT/KR2021/001928 patent/WO2021162532A2/ko unknown
- 2021-02-15 CN CN202180027937.6A patent/CN115484935A/zh active Pending
-
2022
- 2022-03-08 KR KR1020220029577A patent/KR20220035361A/ko not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140004198A1 (en) * | 2011-01-19 | 2014-01-02 | Novo Nordisk A/S | Glp-1 particles and compositions |
JP2016515612A (ja) * | 2013-04-03 | 2016-05-30 | ドン クック ファーマシューティカル カンパニー リミテッド | ドネペジルを含む非経口投与用の医薬組成物 |
WO2017186075A1 (zh) * | 2016-04-26 | 2017-11-02 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
KR102047983B1 (ko) * | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
Non-Patent Citations (1)
Title |
---|
ZOLNIK, B.S., BURGESS, D.J.: "Effect of acidic pH on PLGA microsphere degradation and release", JOURNAL OF CONTROLLED RELEASE, vol. 122, no. 8, 18 September 2007 (2007-09-18), pages 338 - 334, XP022336566, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2007.05.034 * |
Also Published As
Publication number | Publication date |
---|---|
AU2021219556A1 (en) | 2022-09-22 |
WO2021162532A2 (ko) | 2021-08-19 |
EP4104820A4 (en) | 2024-04-17 |
MX2022010044A (es) | 2023-02-22 |
CN115484935A (zh) | 2022-12-16 |
EP4104820A2 (en) | 2022-12-21 |
KR102375262B1 (ko) | 2022-03-16 |
KR102375262B9 (ko) | 2023-04-12 |
BR112022016100A2 (pt) | 2022-10-04 |
CA3167978A1 (en) | 2021-08-19 |
JP2023513751A (ja) | 2023-04-03 |
KR20220035361A (ko) | 2022-03-22 |
KR20210103985A (ko) | 2021-08-24 |
US20230096928A1 (en) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021162532A3 (ko) | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 | |
JP6491174B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
ES2660544T3 (es) | Liberación pulsátil de fármaco | |
ES2659815T3 (es) | Administración inmediata/retardada de fármacos | |
TWI314868B (en) | Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient | |
JP2020058871A5 (ko) | ||
JP2017222705A5 (ko) | ||
JP2020508338A5 (ko) | ||
JP2019517542A5 (ko) | ||
IL183236A0 (en) | Rasagiline orally disintegrating compositions | |
JP2013018786A (ja) | レベチラセタムを含む薬剤組成物及びその調製方法 | |
HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
EP3041511B1 (en) | Compositions of eltrombopag | |
JP2018502898A5 (ko) | ||
JP2020522560A5 (ko) | ||
JP2020514415A5 (ko) | ||
JP2016528171A5 (ko) | ||
US20170231969A1 (en) | Pharmaceutical Compositions of Edoxaban | |
JP2020536121A5 (ko) | ||
CN110753540A (zh) | 瑞格列净的口服药物制剂 | |
JP2020512292A5 (ko) | ||
CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
JP5699339B2 (ja) | 徐放性製剤 | |
IL307997A (en) | Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases | |
WO2020207344A1 (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21754621 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2022548939 Country of ref document: JP Kind code of ref document: A Ref document number: 3167978 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022016100 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021754621 Country of ref document: EP Effective date: 20220914 |
|
ENP | Entry into the national phase |
Ref document number: 2021219556 Country of ref document: AU Date of ref document: 20210215 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022016100 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220812 |